Basic Information
Duloxetine Mylan
Regulatory Information
EMEA/H/C/003981
June 19, 2015
April 23, 2015
21
June 20, 2024
Company Information
Ireland
Damastown Industrial Park Mulhuddart Dublin 15
VIATRIS PHARMA LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication - Treatment of major depressive disorder; - Treatment of diabetic peripheral neuropathic pain; - Treatment of generalised anxiety disorder; - Duloxetine Mylan is indicated in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Duloxetine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Mylan. For practical information about using Duloxetine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.